Neuropace Inc Total Liabilities
Neuropace Inc total liabilities. Based on the latest financial reports, Neuropace Inc (NPCE) has total liabilities worth $85.11 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Neuropace Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Neuropace Inc (2019–2025)
Total liabilities of Neuropace Inc from 2019 to 2025. This chart illustrates how Neuropace Inc's total liabilities have evolved over time, based on quarterly financial data.
Neuropace Inc Competitors by Total Liabilities
The table below lists competitors of Neuropace Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chung Hwa Pulp Corp
TW:1905
|
Taiwan | NT$21.85 Billion |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
China | CN¥857.66 Million |
|
Shenzhen TVT Digital Technology Co Ltd
SHE:002835
|
China | CN¥429.93 Million |
|
Binh Minh Plastics JSC
VN:BMP
|
Vietnam | ₫503.34 Billion |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
Germany | €317.79 Million |
|
InBody Co.Ltd
KQ:041830
|
Korea | ₩36.31 Billion |
|
Pes Camanchaca
SN:CAMANCHACA
|
Chile | CL$423.96 Million |
|
ValueHD Corp. A
SHE:301318
|
China | CN¥169.99 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Neuropace Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Neuropace Inc (NPCE) total assets.
Liquidity & Leverage Metrics
Neuropace Inc Total Liabilities Ratios Explained
Neuropace Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuropace Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuropace Inc (2019–2025)
The table below shows the annual total liabilities of Neuropace Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $86.53 Million | -0.12% |
| 2024-12-31 | $86.63 Million | -0.42% |
| 2023-12-31 | $87.00 Million | +9.67% |
| 2022-12-31 | $79.33 Million | +32.09% |
| 2021-12-31 | $60.06 Million | -70.53% |
| 2020-12-31 | $203.78 Million | +35.45% |
| 2019-12-31 | $150.44 Million | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more